Table 4 |
||||||
|
Studies reporting at least one positive outcome and ≥ 50% significant outcomes in favour of CDSS |
||||||
|
Before Drug Selection (n = 26) n/N (%) |
After Drug Selection (n = 12) n/N (%) |
Monitoring (n = 23) n/N (%) |
||||
|
|
||||||
|
At least one positive outcome |
≥ 50% statistically significant outcomes |
At least one positive outcome |
≥ 50% statistically significant outcomes |
At least one positive outcome |
≥ 50% statistically significant outcomes |
|
|
|
||||||
|
Overall |
24/26 (92) |
12/26 (46) |
12/12 (100) |
7/12 (58) |
18/23 (78) |
8/23 (35) |
|
|
||||||
|
Initiation of CDSS |
||||||
|
System |
19/20 (95) |
12/20 (60) |
12/12 (100) |
7/12 (58) |
9/11 (82) |
6/11 (55) |
|
User |
2/3 (67) |
0/3 (0) |
NA |
NA |
9/11 (82) |
2/11 (18) |
|
Mixed/Unclear |
3/3 (100) |
0/3 (0) |
NA |
NA |
0/1 (0) |
0/1 (0) |
|
|
||||||
|
Clinical Setting |
||||||
|
Institutional |
5/5 (100) |
3/5 (60) |
5/5 (100) |
4/5 (80) |
6/7(86) |
3/7 (43) |
|
Ambulatory Care |
18/20 (90) |
8/20 (40) |
7/7 (100) |
3/7 (43) |
10/14 (71) |
4/14 (29) |
|
Both |
1/1 (100) |
1/1 (100) |
NA |
NA |
2/2 (100) |
1/2 (50) |
|
|
||||||
|
Mode of Delivery |
||||||
|
Multi-faceted |
13/15 (87) |
5/15 (33) |
NA |
NA |
5/7 (71) |
2/7 (29) |
|
CDSS only |
11/11(100) |
7/11 (64) |
12/12 (100) |
7/12 (58) |
13/16 (81) |
6/16 (38) |
|
|
||||||
|
Clinical Area |
||||||
|
Cardiovascular |
13/16 (81) |
4/16 (25) |
1/1 (100) |
0/1 (0) |
2/3 (67) |
1/3 (33) |
|
Antibiotics |
2/2 (100) |
1/2 (50) |
6/6 (100) |
4/6 (67) |
1/1 (100) |
0/1 (0) |
|
Vaccinations |
8/9 (89) |
5/9 (56) |
NA |
NA |
NA |
NA |
|
Respiratory |
1/2 (50) |
0/2 (0) |
3/3 (100) |
1/3 (33) |
2/5 (40) |
1/5 (20) |
|
Anticoagulants |
3/3 (100) |
2/3 (67) |
NA |
NA |
9/9 (100) |
2/9 (22) |
|
Elderly |
NA |
NA |
4/4 (100) |
2/4 (50) |
0/1 (0) |
0/1 (0) |
|
Osteoporosis |
2/2 (100) |
1/2 (50) |
NA |
NA |
NA |
NA |
|
Other |
3/4 (75)a |
3/4 (75)a |
2/2 (100)b |
2/2 (100)b |
5/6 (83)c |
4/6 (67)c |
|
|
||||||
|
a Other clinical areas include: salicylates or paracetamol in patients with history of GI bleed; erythropoietin low Hb; HIV medications; various medications b Other clinical areas include: various medications interacting with warfarin; various conditions in children (e.g. croup, otitis media) c Other clinical areas include: hormone treatment for infertility; etretinate for psoriasis; HIV medications; various conditions (e.g. epilepsy, gout, diabetes). |
||||||
|
Pearson et al. BMC Health Services Research 2009 9:154 doi:10.1186/1472-6963-9-154 |
||||||
